Log in to search using one of your social media accounts:


The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis

Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity ofAR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent.
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news

Related Links:

More News: Aspergillus | Celebrex | Clinical Trials | Cryptococcosis | Fluconazole | Respiratory Medicine | Websites